EP2889310
Mótefnissamsetningar
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
3.7.2008EP published:
20.12.2017EP application number:
15155712.1
EP translation filed:
26.2.2018Grant published:
15.3.2018EPO information:
European Patent Register
Max expiry date:
2.7.2028Expiry date:
2.7.2026Next due date:
31.7.2026
Title:
Antibody formulations
Timeline
Today
3.7.2008EP application
20.12.2017EP Publication
26.2.2018Translation submitted
15.3.2018Registration published
2.7.2026Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056, Basel, CH
Inventor
Name:
Brisbane, Charlene EAddress:
King of Prussia, PA, US
Name:
Ketkar, Amol SharadAddress:
King of Prussia, PA, US
Name:
Lashmar, Ulla ToveAddress:
BrentfordMiddlesex TW8 9GS, GB
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
948220 PDate:
6.7.2007Country:
US
Classification
Categories:
C07K 16/00, A61K 39/395, C07K 16/28, A61K 9/00
Annual fees
Number
Paid
Expires
Payer
Number: 11
Paid: 27.6.2018
Expires: 2.7.2019
Payer: Árnason Faktor
Number: 12
Paid: 25.6.2019
Expires: 2.7.2020
Payer: Árnason Faktor
Number: 13
Paid: 25.6.2020
Expires: 2.7.2021
Payer: Árnason Faktor ehf.
Number: 14
Paid: 24.6.2021
Expires: 2.7.2022
Payer: Árnason Faktor ehf.
Number: 15
Paid: 29.6.2022
Expires: 2.7.2023
Payer: Árnason Faktor ehf.
Number: 16
Paid: 28.6.2023
Expires: 2.7.2024
Payer: Árnason Faktor ehf.
Number: 17
Paid: 24.6.2024
Expires: 2.7.2025
Payer: Árnason Faktor ehf.
Number: 18
Paid: 4.7.2025
Expires: 2.7.2026
Payer: Árnason Faktor ehf.